February 6, 2019

PET Imaging in Potentially Evolving Treatment Paradigms in Alzheimer’s Disease

Virtual 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

An Overview of Alzheimer’s Disease and the Current Treatment Landscape

Paul Schulz, MD, provides a brief overview of the prevalence, economic burden, and pathophysiology of AD. He then discusses the current treatment landscape for AD, before closing the section with an outline of a typical diagnostic journey, highlighting where PET imaging fits in as a valuable tool in the diagnostic workup.

Key Learning Objectives from Biogen’s SNMMI 2021 Symposium:

  • Provide an understanding of AD by examining its pathophysiology, epidemiology, and the treatment landscape
  • Outline the utility of PET imaging for early diagnosis of AD in the context of emerging anti-amyloid therapies
  • Explore PET findings from recent phase 3 clinical trials and through case study discussion, highlight the importance of PET imaging, and identify best practices for neurologists and radiologists to use PET for the diagnosis of AD

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.